T2 Biosystems (NASDAQ:TTOO) : Wednesdays money flow indicated an uptick to downtick ratio was at 8.5. The total value of inflow transactions on upticks was $0.49 million, whereas, the total value of outflow trades on downticks was $0.06 million. The total money flow was $0.43 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $0.42 million. The total value of the trades done on upticks was $0.42 million. T2 Biosystems (NASDAQ:TTOO) was trading with a -0.12% change over previous days close. It fell $0.01 during the day and reached $8.31. The stock was -2.24% compared to the previous weeks close.
In an insider trading activity, The Securities and Exchange Commission has divulged that Dhanda Rahul, officer (SVP of Corporate Development) of T2 Biosystems, Inc., had unloaded 7,588 shares at an average price of $8.02 in a transaction dated on March 16, 2016. The total value of the transaction was worth $60,856. Currently the company Insiders own 60.2% of T2 Biosystems shares according to the proxy statements. Institutional Investors own 76.56% of T2 Biosystems shares.
The company shares have dropped -47.01% from its 1 Year high price. On Jul 10, 2015, the shares registered one year high at $17.27 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $8.65 and the 200 Day Moving Average price is recorded at $9.10. T2 Biosystems (NASDAQ:TTOO): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $8.48 and $8.17 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $8.48. The buying momentum continued till the end and the stock did not give up its gains. It closed at $8.39, notching a gain of 0.84% for the day. The total traded volume was 110,416 . The stock had closed at $8.32 on the previous day.
T2 Biosystems, Inc. is an in vitro diagnostics company that has developed a technology platform offering an alternative to diagnostic methodologies. The Companys T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Companys initial development efforts target sepsis, hemostasis and Lyme disease, areas of significant unmet medical need. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The initial panels designed to run on T2Dx are T2Candida and T2Bacteria, which are focused on identifying life-threatening pathogens associated with sepsis.